Events Partner Content Triple Negative Breast Cancer Drug Development Digital Summi... Fast-track the Discovery & Development of TNBC
Partner Content Partner Content SMi’s HPAPI 2018 Conference: Exclusive Interview Released wi... HPAPI 2018
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
